全文获取类型
收费全文 | 94470篇 |
免费 | 11503篇 |
国内免费 | 6310篇 |
专业分类
耳鼻咽喉 | 1255篇 |
儿科学 | 1335篇 |
妇产科学 | 1210篇 |
基础医学 | 8662篇 |
口腔科学 | 1986篇 |
临床医学 | 13838篇 |
内科学 | 13056篇 |
皮肤病学 | 1073篇 |
神经病学 | 4277篇 |
特种医学 | 3752篇 |
外国民族医学 | 31篇 |
外科学 | 9949篇 |
综合类 | 17773篇 |
现状与发展 | 20篇 |
一般理论 | 5篇 |
预防医学 | 8532篇 |
眼科学 | 1977篇 |
药学 | 10131篇 |
115篇 | |
中国医学 | 6055篇 |
肿瘤学 | 7251篇 |
出版年
2024年 | 478篇 |
2023年 | 1904篇 |
2022年 | 3851篇 |
2021年 | 4867篇 |
2020年 | 4045篇 |
2019年 | 2911篇 |
2018年 | 3401篇 |
2017年 | 3401篇 |
2016年 | 3257篇 |
2015年 | 4809篇 |
2014年 | 5675篇 |
2013年 | 5943篇 |
2012年 | 7235篇 |
2011年 | 7725篇 |
2010年 | 5955篇 |
2009年 | 5126篇 |
2008年 | 5339篇 |
2007年 | 5286篇 |
2006年 | 4905篇 |
2005年 | 4206篇 |
2004年 | 3311篇 |
2003年 | 3085篇 |
2002年 | 2704篇 |
2001年 | 2209篇 |
2000年 | 1752篇 |
1999年 | 1434篇 |
1998年 | 1004篇 |
1997年 | 1081篇 |
1996年 | 859篇 |
1995年 | 720篇 |
1994年 | 573篇 |
1993年 | 404篇 |
1992年 | 400篇 |
1991年 | 361篇 |
1990年 | 334篇 |
1989年 | 301篇 |
1988年 | 241篇 |
1987年 | 223篇 |
1986年 | 191篇 |
1985年 | 139篇 |
1984年 | 108篇 |
1983年 | 77篇 |
1982年 | 46篇 |
1981年 | 64篇 |
1980年 | 46篇 |
1979年 | 56篇 |
1978年 | 34篇 |
1976年 | 25篇 |
1975年 | 27篇 |
1974年 | 24篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
3.
4.
5.
6.
Xin Yi Wong Andrew Qi Jun Lim Qianyu Shen John Whay Kuang Chia Min Hoe Chew Wah Siew Tan 《Current medical research and opinion》2020,36(10):1677-1686
Abstract
Objective
Ras wild-type metastatic colorectal cancers (mCRC) may be treated with anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor receptor (EGFR) agents. We aim to estimate patients’ preferences for mCRC treatment and relative importance of cost, efficacy improvement, avoidance of side effects and therapy convenience, and relative uptake between profiles that resemble Bevacizumab (anti-VEGF) and Cetuximab (anti-EGFR), two commonly prescribed mCRC targeted therapies. 相似文献7.
8.
Sophocarpine attenuates toll‐like receptor 4 in steatotic hepatocytes to suppress pro‐inflammatory cytokines synthesis
下载免费PDF全文
![点击此处可从《Journal of gastroenterology and hepatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
9.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies
下载免费PDF全文
![点击此处可从《Journal of viral hepatitis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
10.